CAR-T Meeting 2024 | Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells
Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, comments on his recent publication, which explored the dual targeting of the cancer metabolome and stress antigens and how this may affect the efficacy of engineered T-cells to improve patient outcomes. Dr Kuball shares that this approach was used to achieve a cure in complicated mouse models, presenting an exciting potential avenue for cancer treatment. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Patents:
Exclusively licensed to Gadeta.
• WO2013147606 COMBINATORIAL GAMMA 9 DELTA 2 T CELL RECEPTOR CHAIN EXCHANGE
• WO2017212074 NOVEL METHOD FOR IDENTIFYING DELTAT-CELL (OR GAMMAT-CELL) RECEPTOR CHAINS OR PARTS THEREOF THAT MEDIATE AN ANTI-TUMOUR OR AN ANTI-INFECTIVE RESPONSE
• WO2017212072 HUMAN LEUKOCYTE ANTIGEN RESTRICTED GAMMA DELTA T CELL RECEPTORS AND METHODS OF USE THEREOF
• WO2018211115 COMPOSITIONS AND METHODS FOR CELL TARGETING THERAPIES
Exclusively licensed to Miltenyi Biotec:
• WO2016079333 USE OF ANTIBODIES FOR ENRICHMENT OF ENGINEERED T CELLS WITH EXOGENOUS IMMUNE RECEPTORS AND ANTIBODIES FOR USE IN DEPLETION OF ENGINEERED T CELLS
Joint patent UMCU with Miltenyi Biotec on “Novel CAR Concepts”:
• WO2020201527 MODIFIED IMMUNE RECEPTOR CONSTRUCTS
